|
|
Volumn 8, Issue 8, 2009, Pages 600-601
|
|
Retuning the immune system: The future of type 1 diabetes therapy?
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
BHT 3021;
C PEPTIDE;
EXENDIN 4;
GLUCAGON LIKE PEPTIDE 1;
INSULIN;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY CD3;
NATALIZUMAB;
OKT 3;
OTELIXIZUMAB;
TEPLIZUMAB;
TYPSABRI;
UNCLASSIFIED DRUG;
ABSENCE OF SIDE EFFECTS;
ANTIGEN EXPRESSION;
ARTICLE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG POTENCY;
DRUG SAFETY;
DRUG TARGETING;
EPSTEIN BARR VIRUS;
HUMAN;
IMMUNE RESPONSE;
IMMUNOLOGICAL TOLERANCE;
IMMUNOMODULATION;
IMMUNOREACTIVITY;
INSULIN BLOOD LEVEL;
INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
PANCREAS ISLET BETA CELL;
PREVALENCE;
PRIORITY JOURNAL;
REGULATORY T LYMPHOCYTE;
TREATMENT RESPONSE;
VIRUS REACTIVATION;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS, TYPE 1;
DRUG DESIGN;
HUMANS;
HYPOGLYCEMIC AGENTS;
INSULIN;
PLASMIDS;
PROINSULIN;
UNITED STATES;
|
|
EID: 68249096707
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2956 Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|